Health on MSN2 小时
FDA Plans to Ban Ineffective Cold Medicine Ingredient—How It Will Affect You
The FDA had proposed removing phenylephrine, a widely used ingredient to treat nasal congestion, from over-the-counter cold ...
FDA proposes ending use of popular decongestant in cold medicines
The US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups.
health enews1 天
Nasal congestion on one side? You may have this condition
A deviated septum occurs when you have two different-sized nasal passageways which can cause one-sided congestion.
Ineffective cough syrup ingredient should be axed officially, FDA says
A panel last year said it found evidence the ingredient, used in many popular medicines, did not aid with nasal congestion.
U.S. FDA proposes ending use of popular decongestant present in cold medicines
The U.S. Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups, as an ...
CBC Online 1380 KCIM7 小时
FDA seeks to pull common but ineffective OTC cold medicine ingredient off the market
The Food and Drug Administration (“FDA”) said on Thursday that they will seek to pull the common ingredient phenylephrine off ...
FDA proposes ending use of decongestant found in many cold, allergy medicines
An extensive review determined that the ingredient, oral phenylephrine, doesn’t actually relieve nasal congestion.
GlobalData on MSN6 小时
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial
The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH ...
Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients ...
Woman's World on MSN1 天
Is Your Toothache Actually a Sinus Infection? How to Tell—and Treat It
Sinus infections (also known as sinusitis) strike more than 30 million Americans each year. And if you’re one of them, you’re ...
Yahoo Finance7 小时
TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with ...
demonstrated a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo. WAYPOINT is a randomized, double-blind trial ...
AstraZeneca announces WAYPOINT trial met both co-primary endpoints
Results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps showed that AstraZeneca (AZN) and ...